Similarly, it has been reported that the CD105 (endoglin) antibody was available for antiangiogenic tumor therapy, and that microtubule-associated protein-2 (MAP-2) antibody could elevate the therapeutic efficacy in spinal cord injury [57,59]. This evidence concerns the gene MAP2 and neoplasm.